#1 Clinical Trials Search in Europe

Interleukin-2

Interleukin-2 (IL-2) is a powerful immune system regulator that has shown promise in treating various medical conditions. This article explores the use of IL-2 in clinical trials for different diseases, including HIV, cancer, autoimmune disorders, and more. We’ll discuss how IL-2 works, its potential benefits, and what researchers are discovering about its effectiveness in treating these conditions.

Table of Contents

What is Interleukin-2?

Interleukin-2, also known as IL-2, is a naturally occurring protein in our body that plays a crucial role in the immune system. It is now being used as a medication to treat various conditions. Interleukin-2 is also referred to as recombinant human interleukin-2 (rhIL-2), aldesleukin, or Proleukin when used as a drug[1][2].

How Interleukin-2 Works

Interleukin-2 is a pleiotropic cytokine, which means it has multiple effects on different cells in the body. It is produced by activated T cells (a type of white blood cell) and plays a central role in the immune response to infections. Interleukin-2 works by:

  • Promoting the growth and multiplication of immune cells, particularly T cells and natural killer (NK) cells
  • Regulating the behavior of various immune cells, including T cells, B cells, monocytes/macrophages, and neutrophils
  • Stimulating the production of other important molecules that help fight infections and diseases

By enhancing the immune system’s function, Interleukin-2 can help the body better fight against various diseases and infections[3].

Medical Conditions Treated with Interleukin-2

Interleukin-2 is being used or studied for the treatment of several medical conditions:

  1. HIV Infection: Researchers are investigating whether Interleukin-2 can help reduce the HIV reservoir (hidden virus) in patients with suppressed HIV infection[1].
  2. Cancer: Interleukin-2 is used in the treatment of certain types of cancer, including:
    • Metastatic Melanoma (advanced skin cancer)[4]
    • Metastatic Renal Cell Carcinoma (advanced kidney cancer)[5]
  3. Autoimmune Diseases: Studies are exploring the use of low-dose Interleukin-2 for various autoimmune conditions, such as:
    • Alopecia Areata (a type of hair loss)[6]
    • Inflammatory Myopathy (muscle inflammation)[7]
    • Polymyalgia Rheumatica (muscle pain and stiffness)[8]
    • Dermatomyositis (a rare inflammatory disease)[9]
  4. Acute Myelogenous Leukemia: Interleukin-2 is being studied as a potential therapy during recovery after chemotherapy for this type of blood cancer[10].
  5. Tuberculosis: Research is ongoing to determine if adding Interleukin-2 to standard tuberculosis treatment can improve outcomes for patients with pulmonary tuberculosis[3].

Administration and Dosage

Interleukin-2 is typically administered through subcutaneous injection (under the skin) or intravenous infusion (into a vein). The dosage and schedule can vary significantly depending on the condition being treated and the specific study or treatment protocol. Some examples include:

  • For HIV studies: 5 million units twice daily for 5 consecutive days every 8 weeks[1]
  • For cancer treatment: Various schedules, such as daily injections for 5 days every 3 weeks[4][5]
  • For autoimmune diseases: Low-dose regimens, such as 1 million units every other day for several months[7][8]

It’s important to note that the dosage and administration should always be determined and supervised by a healthcare professional.

Potential Benefits

The potential benefits of Interleukin-2 therapy vary depending on the condition being treated. Some possible benefits include:

  • Reduction of HIV reservoirs in patients with controlled HIV infection[1]
  • Tumor shrinkage in certain types of cancer[4][5]
  • Improvement in symptoms of autoimmune diseases[7][8]
  • Enhanced immune function during recovery from cancer treatments[10]
  • Potential improvement in tuberculosis treatment outcomes[3]

Side Effects and Safety

Like all medications, Interleukin-2 can cause side effects. The severity and frequency of side effects can vary depending on the dosage and individual patient factors. Some potential side effects include:

  • Fever
  • Rash
  • Abnormal liver function
  • Increased risk of infections

It’s important to discuss potential side effects with your healthcare provider before starting treatment. They will monitor you closely during therapy to manage any adverse effects[9].

Ongoing Research

Interleukin-2 continues to be the subject of numerous clinical trials and research studies. Scientists are exploring its potential in various areas, including:

  • Optimizing dosages and treatment schedules for different conditions
  • Combining Interleukin-2 with other therapies to enhance effectiveness
  • Investigating its use in additional autoimmune diseases and infections
  • Studying long-term effects and outcomes in patients treated with Interleukin-2

As research progresses, our understanding of Interleukin-2’s potential benefits and optimal use in various conditions continues to grow[1][3].

Condition IL-2 Dosage Administration Key Findings
HIV Infection 5 MIU twice daily for 4 consecutive days every 8 weeks Subcutaneous Potential reduction in HIV reservoir size
Metastatic Melanoma Moderate dose bolus Not specified Evaluation of tumor shrinkage and response rate
Metastatic Kidney Cancer Moderate dose bolus Not specified Assessment of tumor response and survival rates
Alopecia Areata 1.5-3 MIU/day for 5-7 days, 4 cycles Subcutaneous Evaluation of hair regrowth and quality of life improvement
Inflammatory Myopathy 1 million units every other day for 3 months Subcutaneous Assessment of clinical and immunological efficacy
Polymyalgia Rheumatica 1 million units, 5 days/week for 4 weeks, then weekly for 8 weeks Subcutaneous Exploration of clinical and immunological efficacy
Dermatomyositis 1 million IU every other day for 6 months Subcutaneous Evaluation of efficacy and safety in refractory cases
Acute Myelogenous Leukemia 18 million IU/m2 daily for 5 days Intravenous Assessment of immunotherapy benefit during lymphocyte recovery

FAQ

  • What is Interleukin-2 and how does it work? Interleukin-2 (IL-2) is a naturally occurring protein in the body that helps regulate the immune system. It plays a crucial role in the growth, development, and function of certain white blood cells called T cells. In clinical trials, synthetic IL-2 is used to boost the immune system's ability to fight various diseases.
  • What conditions are being studied with Interleukin-2 treatment? Clinical trials are exploring the use of IL-2 in various conditions, including HIV infection, metastatic melanoma, kidney cancer, alopecia areata, inflammatory myopathy, polymyalgia rheumatica, dermatomyositis, and acute myelogenous leukemia.
  • How is Interleukin-2 administered in clinical trials? IL-2 is typically administered through subcutaneous injections. The dosage and frequency vary depending on the condition being treated and the specific trial protocol. Some trials use low-dose IL-2, while others use moderate or high doses.
  • What are the potential benefits of Interleukin-2 treatment? Potential benefits of IL-2 treatment include boosting the immune system, reducing HIV viral reservoirs, shrinking tumors in cancer patients, improving symptoms in autoimmune disorders, and potentially inducing remission in some conditions.
  • Are there any side effects associated with Interleukin-2 treatment? Side effects of IL-2 treatment can vary depending on the dosage and individual patient factors. Common side effects may include fever, fatigue, skin rashes, and flu-like symptoms. More severe side effects are possible, especially with higher doses, which is why patients are closely monitored during clinical trials.

Ongoing Clinical Trials on Interleukin-2

  • Study on the Effectiveness of 2LPAPI with Interferon Alfa in Clearing Genital HPV Infections in Patients

    Recruiting

    1 1 1
    Investigated drugs:
    Belgium Romania

  • Study on the Effectiveness of Interferon Alfa, Interleukin-1, and Interleukin-2 in Treating Non-Genital Warts in Patients

    Recruiting

    1 1 1
    Investigated drugs:
    Belgium

  • Study on the Effectiveness of 2LEBV and 2LXFS for Reducing Fatigue in Patients with Epstein-Barr Virus Infection

    Recruiting

    1 1 1
    Investigated drugs:
    Belgium

Glossary

  • Interleukin-2 (IL-2): A protein naturally produced by the body that regulates the immune system, particularly the growth and activity of T cells. Synthetic versions are used in clinical trials to treat various conditions.
  • T cells: A type of white blood cell that plays a central role in the immune response, helping to identify and fight off foreign invaders in the body.
  • CD4+ cells: A type of T cell that helps coordinate the immune response. They are often targeted by HIV, making them an important focus in HIV treatment studies.
  • Viral reservoir: A place in the body where viruses, such as HIV, can persist even when they are undetectable in the blood, making complete eradication difficult.
  • Regulatory T cells (Treg): A subpopulation of T cells that help maintain balance in the immune system and prevent autoimmune diseases.
  • Subcutaneous injection: A method of administering medication by injecting it into the layer of tissue between the skin and muscle.
  • Metastatic: Referring to cancer that has spread from its original site to other parts of the body.
  • Alopecia areata: An autoimmune disorder that causes hair loss in patches on the scalp or other parts of the body.
  • Dermatomyositis: A rare inflammatory disease characterized by muscle weakness and skin rash.
  • Polymyalgia rheumatica: An inflammatory disorder that causes muscle pain and stiffness, particularly in the shoulders and hips.

References

  1. https://clinicaltrials.gov/study/NCT03308786
  2. https://clinicaltrials.gov/study/NCT00004978
  3. https://clinicaltrials.gov/study/NCT04766307
  4. https://clinicaltrials.gov/study/NCT01702896
  5. https://clinicaltrials.gov/study/NCT01702909
  6. https://clinicaltrials.gov/study/NCT01840046
  7. https://clinicaltrials.gov/study/NCT04062019
  8. https://clinicaltrials.gov/study/NCT04062006
  9. https://clinicaltrials.gov/study/NCT05495321
  10. https://clinicaltrials.gov/study/NCT01289678